SCHEMBL19682008

SCHEMBL19682008

CNc1ccc(Cc2ccc(C)cc2)cc1OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.53
ALDH1A1 P00352 4/20 0.49
APP P05067 2/20 0.45
GAA P10253 1/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
EPHX2 P34913 1/20 0.42
MAPT P10636 1/20 0.42
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41
TUBA4A P68366 1/20 0.41
TUBB4B P68371 1/20 0.41
TUBB3 Q13509 1/20 0.41
TUBB2A Q13885 1/20 0.41
TUBB8 Q3ZCM7 1/20 0.41
TUBA3E Q6PEY2 1/20 0.41
TUBA1A Q71U36 1/20 0.41
TUBA1C Q9BQE3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2755832 0.81 ACHE (0.58) ALDH1A1APPLMNASMN1; SMN2POLB
SCHEMBL27403165 0.79 APP (0.47) CA2ALDH1A1APPGAATUBB4A
SCHEMBL21019867 0.77 ATM (0.50) CA2ALDH1A1APPSMN1; SMN2MAPT
SCHEMBL22601651 0.77 ALDH1A1 (0.82) CA2ALDH1A1GAALMNASMN1; SMN2
SCHEMBL19805995 0.76 FOS (0.47) CA2ALDH1A1APPMAPTPOLB
SCHEMBL27704501 0.75 AKR1B1 (0.53) CA2ALDH1A1GAALMNASMN1; SMN2
SCHEMBL19682010 0.75 CA2 (0.52) CA2ALDH1A1APPGAALMNA
SCHEMBL21933490 0.74 TUBB4A (0.68) CA2GAALMNASMN1; SMN2MAPT
SCHEMBL27403166 0.73 APP (0.43) CA2ALDH1A1APPGAAMAPT
SCHEMBL27296853 0.72 CA2 (0.53) CA2ALDH1A1GAALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3901162-A1 GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF AbbVie Inc. (US) 2021-10-27 EP disclosed
US-20200338208-A1 GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF ABBVIE INC. (US) 2020-10-29 US disclosed
WO-2017207776-A1 SYSTEM FOR DISPENSING A COSMETIC PRODUCT L'OREAL (FR) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200338208-A1 GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF NR3C1, NR3C2, MC2R CA2 4561/4885ALDH1A1 3434/4885APP 4433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.